Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway
Minda Zhang1, Chenyu Jin1, Yunjia Yang1
1State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, China.
Abstract:
The human absent in melanoma 2 (AIM2) is considered as a DNA recognizer. AIM2 has been described as a tumor suppressor gene in the early years. But recent studies suggested that it functions as an oncogene in several cancers. However, its roles in non-small-cell lung cancer (NSCLC) remain unclear. Here we reported that AIM2 highly expressed in NSCLC cells and exhibited a tumor-promoting property both in vitro and in vivo. Besides, AIM2 short hairpin RNA (shRNA)-mediated suppression of cell proliferation was triggered by the accumulation of cells at the G2/M phase. Knockdown of AIM2 reduced the inflammasome formation, while overexpression of AIM2 or stimulation by poly(dA:dT) induced the inflammasome formation. Interestingly, blockade of the inflammasome by caspase-1 inhibitor VX-765 or ASC small interfering RNA (siRNA) abolished the effects brought by AIM2 shRNA and AIM2 plasmid. In summary, our results revealed that AIM2 functioned as an oncogene in NSCLC in an inflammasome-dependent way.
Insights
The human absent in melanoma 2 (AIM2) gene promotes non-small-cell lung cancer (NSCLC) growth by activating the inflammasome pathway. Suppressing AIM2 halts cancer cell proliferation and tumor development in NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The human absent in melanoma 2 (AIM2) is a DNA sensor with debated roles in cancer.
- Previous research indicated AIM2 as a tumor suppressor, but recent findings suggest oncogenic functions in various cancers.
- The specific role of AIM2 in non-small-cell lung cancer (NSCLC) remains largely undetermined.
Purpose of the Study:
- To investigate the role of AIM2 in non-small-cell lung cancer (NSCLC).
- To elucidate the underlying mechanism of AIM2's function in NSCLC progression.
Main Methods:
- Quantitative analysis of AIM2 expression in NSCLC cells.
- In vitro and in vivo assays to assess tumor-promoting properties.
- AIM2 knockdown using short hairpin RNA (shRNA) and overexpression studies.
- Assessment of cell cycle progression (G2/M phase).
- Analysis of inflammasome formation and activation.
- Inhibition of inflammasome pathway using caspase-1 inhibitor (VX-765) and ASC siRNA.
Main Results:
- AIM2 is highly expressed in NSCLC cells, indicating a tumor-promoting role.
- AIM2 suppression via shRNA led to cell proliferation arrest at the G2/M phase.
- AIM2 modulated inflammasome formation; knockdown reduced it, while overexpression or poly(dA:dT) stimulation induced it.
- Inflammasome blockade reversed the effects of AIM2 manipulation on cell proliferation.
Conclusions:
- AIM2 functions as an oncogene in non-small-cell lung cancer (NSCLC).
- AIM2 promotes NSCLC progression through an inflammasome-dependent mechanism.
- Targeting AIM2 or the inflammasome pathway may offer therapeutic strategies for NSCLC.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
cAMP-dependent Protein Kinase Pathways
Cells Coordinate Growth and Proliferation
The Eukaryotic Promoter Region
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Cancer Cell Migration through Invadopodia

